5 years ago

Endomag Secures £15 Million in Series D Funding to Expand Breast Cancer Solutions

  • Endomag, a UK-based developer of tech solutions for breast cancer, has raised £15 million in Series D funding led by Draper Esprit, with participation from existing investors such as Sussex Place Ventures

  • The funding will be used to expand access to new advanced techniques enabled by Endomag's products, such as targeted axillary dissection (TAD) and delayed sentinel lymph node biopsy (dSLNB), and to scale its product offering, market reach, and employee base

  • Endomag's Sentimag® localisation system uses non-invasive magnetic sensing to locate and stage breast cancer

  • The company continues to invest in research and development and is set to launch its next-generation Sentimag® platform and new Magseed® products in 2021

  • Endomag aims to expand beyond its current base of 43 countries.

      • ProblemHealthcare

      "Breast cancer diagnosis and surgery are often complex and invasive, leading to unnecessary tissue removal and longer recovery times."

      Solution

      "Endomag provides a non-invasive magnetic sensing technology for locating and staging breast cancer, enabling more precise and targeted surgery, leading to faster recovery and less tissue damage."

      Covered on